Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.

This content is available also in other languages

x

This content is available also in other languages

January 8, 2018 | Corporate News | English

Tecan to present at J.P. Morgan Healthcare Conference

Männedorf, Switzerland, January 8, 2018 - The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will present at J.P. Morgan Healthcare Conference on January 11, 2018.

The investor presentation by David Martyr, CEO of Tecan, will begin at 9:30 am PST (6:30 pm CET) and will be webcast live. The webcast may be accessed under the "Investor Relations" tab of Tecan's website www.tecan.com.

A replay of the webcast will be available after the presentation and will remain available for 90 days.

 

About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manu­facturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2016, Tecan generated sales of CHF 506 million (USD 511 million; EUR 464 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

 

For further information:
Tecan Group

Martin Braendle
Vice President, Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com


Downloads: